HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 5, 2014, Pages

  Palmer, Suetonia C ^a   Navaneethan, Sankar D ^b   Craig, Jonathan C ^c,d   Johnson, David W ^e   Perkovic, Vlado ^f   Hegbrant, Jorgen ^g   Strippoli, Giovanni F M ^c,d,h,i,j,k  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF SYDNEY   (Australia)

^d CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^e PRINCESS ALEXANDRA HOSPITAL   (Australia)

^f GEORGE INSTITUTE FOR GLOBAL HEALTH   (Australia)

^g Diaverum Renal Services Group   (Sweden)

^h UNIVERSITY OF BARI   (Italy)

ⁱ MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^j Diaverum   (Sweden)

^k UNIVERSITY OF EASTERN PIEDMONT   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; CREATINE KINASE; CREATININE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PITAVASTATIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ALL CAUSE MORTALITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY FAILURE; CREATININE CLEARANCE; DRUG WITHDRAWAL; END STAGE RENAL DISEASE; HEART INFARCTION; HUMAN; HYPERTRANSAMINASEMIA; MALIGNANT NEOPLASM; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; RISK BENEFIT ANALYSIS; RISK REDUCTION; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; ADULT; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; COMPLICATION; DISEASE COURSE; HYPERLIPIDEMIAS; KIDNEY DISEASE; MORTALITY; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL REPLACEMENT THERAPY; STROKE;

ADULT; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; DISEASE PROGRESSION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; KIDNEY DISEASES; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL DIALYSIS; STROKE;

EID: 84942772639     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD007784.pub2     Document Type: Review

References (393)

1. Anonymous. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet 1995;345(8960):1274-5. [MEDLINE: 7746058].
2. Anonymous. Design and baseline results of the Scandinavian Simvastatin Survival Study of patients with stable angina and/or previous myocardial infarction. American Journal of Cardiology 1993;71(5):393-400. [MEDLINE: 8430625].
3. Anonymous. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344(8934):1383-9. [MEDLINE: 7968073].
4. Ballantyne CM, Olsson AG, Cook TJ, Mercuri MF, Pedersen TR, Kjekshus J. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 2001;104(25):3046-51. [MEDLINE: 11748098].
5. Berg K, Dahlén G, Christophersen B, Cook T, Kjekshus J, Pedersen T. Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study. Clinical Genetics 1997;52(5):254-61. [MEDLINE: 9520115].
6. Chonchol M, Cook T, Kjekshus J, Pedersen TR, Lindenfeld J. Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency. American Journal of Kidney Diseases 2007;49(3):373-82. [MEDLINE: 17336698].
7. Crea F, Monaco C, Lanza GA, Maggi E, Ginnetti F, Cianflone D, et al.Inflammatory predictors of mortality in the Scandinavian Simvastatin Survival Study. Clinical Cardiology 2002;25(10):461-6. [MEDLINE: 12375804].
8. Faergeman O, Kjekshus J, Cook T, Pyorälä K, Wilhelmsen L, Thorgeirsson G, et al.Differences in the treatment of coronary heart disease between countries as revealed in the Scandinavian Simvastatin Survival Study (4S). European Heart Journal 1998;19(10):1531-7. [MEDLINE: 9820992].
9. Gerdes LU, Gerdes C, Kervinen K, Savolainen M, Klausen IC, Hansen PS, et al.The apolipoprotein 4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: a substudy of the Scandinavian simvastatin survival study. Circulation 2000;101(12):1366-71. [MEDLINE: 10736278].
10. Haffner SM. The Scandinavian Simvastatin Survival Study (4S) subgroup analysis of diabetic subjects: implications for the prevention of coronary heart disease. Diabetes Care 1997;20(4):469-71. [MEDLINE: 9096961].
11. Haffner SM, Alexander CM, Cook TJ, Boccuzzi SJ, Musliner TA, Pedersen TR, et al.Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Archives of Internal Medicine 1999;159(22):2661-7. [MEDLINE: 10597756].
12. Herman WH, Alexander CM, Cook JR, Boccuzzi SJ, Musliner TA, Pedersen TR, et al.Effect of simvastatin treatment on cardiovascular resource utilization in impaired fasting glucose and diabetes. Findings from the Scandinavian Simvastatin Survival Study. Diabetes Care 1999;22(11):1771-8. [MEDLINE: 10546006].
13. Huskey J, Lindenfeld J, Cook T, Kjekshus J, Pedersen T. Effect of simvastatin on kidney function loss in patients with coronary heart disease [abstract no: SU-FC137]. Journal of the American Society of Nephrology 2007;18(Abstracts):98A-9A. [CENTRAL: CN-00708811].
14. Huskey J, Lindenfeld J, Cook T, Targher G, Kendrick J, Kjekshus J, et al.Effect of simvastatin on kidney function loss in patients with coronary heart disease: findings from the Scandinavian Simvastatin Survival Study (4S). Atherosclerosis 2009;205(1):202-6. [MEDLINE: 19124121].
15. Johannesson M, Jonsson B, Kjekshus J, Olsson AG, Pedersen TR, Wedel H. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. New England Journal of Medicine 1997;336(5):332-6. [MEDLINE: 9011785].
16. Jonsson B, Cook JR, Pedersen TR. The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial. Diabetologia 1999;42(11):1293-301. [MEDLINE: 10550412].
17. Jönsson B, Johannesson M, Kjekshus J, Olsson AG, Pedersen TR, Wedel H. Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S). European Heart Journal 1996;17(7):1001-7. [MEDLINE: 8809516].
18. Miettinen TA, Gylling H, Strandberg T, Sarna S. Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study. Finnish 4S Investigators. BMJ 1998;316(7138):1127-30. [MEDLINE: 9552949].
19. Miettinen TA, Gylling H, Subgroup analysis of Scandinavian Simvastatin Survival Study (4S). Blood glucose and the metabolism of cholesterol in coronary patients with and without simvastatin treatment. Clinica Chimica Acta 2007;379(1-2):53-8. [MEDLINE: 17258182].
20. Miettinen TA, Pyorälä K, Olsson AG, Musliner TA, Cook TJ, Faergeman O, et al.Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation 1997;96(12):4211-8. [MEDLINE: 9416884].
21. Pedersen TR, Berg K, Cook TJ, Faergeman O, Haghfelt T, Kjekshus J, et al.Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Archives of Internal Medicine 1996;156(18):2085-92. [MEDLINE: 8862101].
22. Pedersen TR, Kjekshus J, Berg K, Haghfelt T, Faergeman O, Faergeman G, et al.Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. Atherosclerosis Supplements 2004;5(3):81-7. [MEDLINE: 15531279].
23. Pedersen TR, Kjekshus J, Berg K, Olsson AG, Wilhelmsen L, Wedel H, et al.Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study. [Erratum appears in Circulation 1996 Aug 15;94(4):849]. Circulation 1996;93(10):1796-802. [MEDLINE: 8635258].
24. Pedersen TR, Kjekshus J, Pyorälä K, Olsson AG, Cook TJ, Musliner TA, et al.Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). American Journal of Cardiology 1998;81(3):333-5. [MEDLINE: 9468077].
25. Pedersen TR, Olsson AG, Faergeman O, Kjekshus J, Wedel H, Berg K, et al.Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 1998;97(15):1453-60. [MEDLINE: 9576425].
26. Pedersen TR, Wilhelmsen L, Faergeman O, Strandberg TE, Thorgeirsson G, Troedsson L, et al.Follow-up study of patients randomized in the Scandinavian Simvastatin Survival Study (4S) of cholesterol lowering. American Journal of Cardiology 2000;86(3):257-62. [MEDLINE: 10922429].
27. Pyorälä K, Ballantyne CM, Gumbiner B, Lee MW, Shah A, Davies MJ, et al.Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 2004;27(7):1735-40. [MEDLINE: 15220255].
28. Pyorälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S).[Erratum appears in Diabetes Care 1997 Jun;20(6):1048]. Diabetes Care 1997;20(4):614-20. [MEDLINE: 9096989].
29. Strandberg TE, Pyorälä K, Cook TJ, Wilhelmsen L, Faergeman O, Thorgeirsson G, et al.Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 2004;364(9436):771-7. [MEDLINE: 15337403].
30. Wilhelmsen L, Pyorälä K, Wedel H, Cook T, Pedersen T, Kjekshus J. Risk factors for a major coronary event after myocardial infarction in the Scandinavian Simvastatin Survival Study (4S). Impact of predicted risk on the benefit of cholesterol-lowering treatment. European Heart Journal 2001;22(13):1119-27. [MEDLINE: 11428852].
31. Clearfield M, Downs JR, Weis S, Whitney EJ, Kruyer W, Shapiro DR, et al.Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): efficacy and tolerability of long-term treatment with lovastatin in women. Journal of Womens Health & Gender-Based Medicine 2001;10(10):971-81. [MEDLINE: 11788107].
32. Clearfield M, Whitney EJ, Weis S, Downs JR, Shapiro DR, Stein EA, et al.Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): baseline characteristics and comparison with USA population. Journal of Cardiovascular Risk 2000;7(2):125-33. [MEDLINE: 10879416].
33. Clearfield MB, Weis SE, Willis JM, Vasenius KA, McConathy WJ. Lability of serum low-density lipoprotein cholesterol levels during screening in subgroup of Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) cohort. Journal of the American Osteopathic Association 2002;102(7):377-84. [MEDLINE: 12138952].
34. Cui Y, Watson DJ, Girman CJ, Shapiro DR, Gotto AM, Hiserote P, et al.Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study). American Journal of Cardiology 2009;104(6):829-34. [MEDLINE: 19733719].
35. Downs JR, Beere PA, Whitney E, Clearfield M, Weis S, Rochen J, et al.Design & rationale of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). American Journal of Cardiology 1997;80(3):287-93. [MEDLINE: 9264420].
36. Downs JR, Clearfield M, Tyroler HA, Whitney EJ, Kruyer W, Langendorfer A, et al.Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin. American Journal of Cardiology 2001;87(9):1074-9. [MEDLINE: 11348605].
37. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al.Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279(20):1615-22. [MEDLINE: 9613910].
38. Gotto AM, Boccuzzi SJ, Cook JR, Alexander CM, Roehm JB, Meyer GS, et al.Effect of lovastatin on cardiovascular resource utilization and costs in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). AFCAPS/TexCAPS Research Group. American Journal of Cardiology 2000;86(11):1176-81. [MEDLINE: 11090787].
39. Kendrick J, Shlipak MG, Targher G, Cook T, Lindenfeld J, Chonchol M. Effect of lovastatin on primary prevention of cardiovascular events in mild CKD and kidney function loss: a post hoc analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study. American Journal of Kidney Diseases 2010;55(1):42-9. [MEDLINE: 19932541].
40. Isaacsohn JL, Davidson MH, Hunninghake D, Singer R, McLain R, Black DM. Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE)-rationale and design of atorvastatin versus usual care in hypercholesterolemic patients with coronary artery disease. American Journal of Cardiology 2000;86(2):250-2. [MEDLINE: 10913499].
41. Koren MJ, Davidson MH, Wilson DJ, Fayyad RS, Zuckerman A, Reed DP, et al.Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD. American Journal of Kidney Diseases 2009;53(5):741-50. [MEDLINE: 19216014].
42. Koren MJ, Hunninghake DB, ALLIANCE Investigators. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the ALLIANCE study. Journal of the American College of Cardiology 2004;44(9):1772-9. [MEDLINE: 15519006].
43. Mullins CD, Rattinger GB, Kuznik A, Koren MJ. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study. Clinical Therapeutics 2008;30 Pt 2:2204-16. [MEDLINE: 19281915].
44. Aranda Arcas JL, Sanchez R, Guijarro C, Araque A, Pulido F, Praga M, et al.Effect of pravastatin on hypercholesterolemia associated with proteinuria. Anales de Medicina Interna 1994;11(11):523-7. [MEDLINE: 7654898].
45. Gupta AK, Chang CL, Dahlof B, Poulter NR, Sever PS. Cardiovascular and all-cause mortality outcomes among hypertensive patients with moderate renal dysfunction in the ASCOT-LLA, and its extended follow-up [abstract]. Journal of Human Hypertension 2011;25(10):633-4.
46. Gupta, AK, Chang CL, Dahlof B, Poulter NR, Sever PS. Cardiovascular and all-cause mortality outcomes among hypertensive patients with moderate renal dysfunction in the ASCOT-LLA, and its extended follow-up [abstract]. European Heart Journal 2011;32:220.
47. Lindgren P, Buxton M, Kahan T, Poulter NR, Dahlof B, Sever PS, et al.Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). European Journal of Cardiovascular Prevention & Rehabilitation 2005;12(1):29-36. [MEDLINE: 15703503].
48. Sever PS, Chang CL, Gupta AK, Whitehouse A, Poulter NR, ASCOT Investigators. The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K. European Heart Journal 2011;32(20):2525-32. [MEDLINE: 21873710].
49. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al.Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Drugs 2004;64 Suppl 2:43-60. [MEDLINE: 15765890].
50. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al.Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361(9364):1149-58. [MEDLINE: 12686036].
51. Sever PS, Poulter NR, Dahlof B, Wedel H, ASCOT Investigators. Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension. Journal of Hypertension 2009;27(5):947-54. [MEDLINE: 19318984].
52. Sever PS, Poulter NR, Dahlof B, Wedel H, Beevers G, Caulfield M, et al.The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure. European Heart Journal 2008;29(4):499-508. [MEDLINE: 18175773].
53. Sever PS, Poulter NR, Dahlof B, Wedel H, Collins R, Beevers G, et al.Reduction in cardiovascular events with atorvastatin in 2, 532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). Diabetes Care 2005;28(5):1151-7. [MEDLINE: 15855581].
54. Bianchi S, Bigazzi R, Caiazza A, Campese VM. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. American Journal of Kidney Diseases 2003;41(3):565-70. [MEDLINE: 12612979].
55. Buemi M, Allegra A, Corica F, Aloisi C, Giacobbe M, Pettinato G, et al.Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy. Clinical Pharmacology & Therapeutics 2000;67(4):427-31. [MEDLINE: 10801253].
56. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al.Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). American Journal of Kidney Diseases 2009;54(5):810-9. [MEDLINE: 19540640].
57. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al.Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364(9435):685-96. [MEDLINE: 15325833].
58. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al.Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia 2005;48(12):2482-5. [MEDLINE: 16284747].
59. Hitman GA, Colhoun H, Newman C, Szarek M, Betteridge DJ, Durrington PN, et al.Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetic Medicine 2007;24(12):1313-21. [MEDLINE: 17894827].
60. Neil HA, DeMicco DA, Luo D, Betteridge DJ, Colhoun HM, Durrington PN, et al.Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes Care 2006;29(11):2378-84. [MEDLINE: 17065671].
61. Newman CB, Szarek M, Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, et al.The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes & Vascular Disease Research 2008;5(3):177-83. [MEDLINE: 18777490].
62. Raikou M, McGuire A, Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, et al.Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia 2007;50(4):733-40. [MEDLINE: 17265034].
63. Soedamah-Muthu SS, Colhoun HM, Thomason MJ, Betteridge DJ, Durrington PN, Hitman GA, et al.The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease. Atherosclerosis 2003;167(2):243-55. [MEDLINE: 12818407].
64. Thomason MJ, Colhoun HM, Livingstone SJ, Mackness MI, Betteridge DJ, Durrington PN, et al.Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes. Diabetic Medicine 2004;21(8):901-5. [MEDLINE: 15270795].
65. Di Lullo L, Addesse R, Comegna C, Firmi G, Galderisi C, Iannacci GR, et al.Effects of fluvastatin treatment on lipid profile, C-reactive protein trend, and renal function in dyslipidemic patients with chronic renal failure. Advances in Therapy 2005;22(6):601-12. [MEDLINE: 16510377].
66. Dummer CD, Thome' FS, Zingano B, Lindoso A, Veronese FV. Acute effect of simvastatin on inflammation and oxidative stress in chronic kidney disease. Journal of Nephrology 2008;21(6):900-8. [MEDLINE: 19034875].
67. Ruggenenti P, Perna A, Tonelli M, Loriga G, Motterlini N, Rubis N, et al.Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE Trial. Clinical Journal of the American Society of Nephrology: CJASN 2010;5(11):1928-38. [MEDLINE: 20671225].
68. Fassett RG, Coombes JS, Packham D, Fairley KF, Kincaid-Smith P. Effect of pravastatin on kidney function and urinary protein excretion in autosomal dominant polycystic kidney disease. Scandinavian Journal of Urology & Nephrology 2010;44(1):56-61. [MEDLINE: 20034362].
69. Fried LF, Forrest KY, Ellis D, Chang Y, Silvers N, Orchard TJ. Lipid modulation in insulin-dependent diabetes mellitus: effect on microvascular outcomes. Journal of Diabetes & its Complications 2001;15(3):113-9. [MEDLINE: 11358679].
70. Gheith O, Saad M, Sobh M. Nephrotic dyslipidemia, harvest of treatment [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:258. [CENTRAL: CN-00509210].
71. Gheith O, Sobh M, Gazaren S, Ahmed H, El Baz M. Study the effect of treatment of nephrotic dyslipidemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome [abstract no: M182]. Nephrology Dialysis Transplantation 2002;17(Suppl 1):100. [CENTRAL: CN-00520338].
72. Gheith OA, Sobh MA, Mohamed KE, El Baz M, El Husseini F, Gazarin SS, et al.Impact of treatment of dyslipidemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome. Nephron 2002;91(4):612-9. [MEDLINE: 12138263].
73. Goicoechea M, de Vinuesa SG, Lahera V, Cachofeiro V, Gomez-Campdera F, Vega A, et al.Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease. Journal of the American Society of Nephrology 2006;17(12 Suppl 3):S231-5. [MEDLINE: 17130267].
74. Hommel E, Andersen P, Gall MA, Nielsen F, Jensen B, Rossing P, et al.Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy. Diabetologia 1992;35(5):447-51. [MEDLINE: 1521727].
75. Collins R, Armitage J, Parish S, Sleigh P, Peto R, Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361(9374):2005-16. [MEDLINE: 12814710].
76. Collins R, Armitage J, Parish S, Sleight P, Peto R, Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004;363(9411):757-67. [MEDLINE: 15016485].
77. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360(9326):23-33. [MEDLINE: 12114037].
78. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360(9326):7-22. [MEDLINE: 12114036].
79. Heart Protection Study Collaborative Group. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20, 536 people with peripheral arterial disease and other high-risk conditions. Journal of Vascular Surgery 2007;45(4):645-54. [MEDLINE: 17398372].
80. Heart Protection Study Collaborative Group. The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20, 536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393]. BMC Medicine 2005;3:6. [MEDLINE: 15771782].
81. Heart Protection Study Collaborative Group, Emberson JR, Ng LL, Armitage J, Bowman L, Parish S, et al.N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20, 536 patients in the MRC/BHF heart protection study. Journal of the American College of Cardiology 2007;49(3):311-9. [MEDLINE: 17239712].
82. Mihaylova B, Briggs A, Armitage J, Parish S, Gray A, Collins R, et al.Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20, 536 individuals. Lancet 2005;365(9473):1779-85. [MEDLINE: 15910950].
83. Holme I, Cater NB, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, et al.Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease In End-points Through Aggressive Lipid-lowering Trial (IDEAL). Annals of Medicine 2008;40(6):456-64. [MEDLINE: 19160529].
84. Holme I, Fayyad R, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, et al.Cardiovascular outcomes and their relationships to lipoprotein components in patients with and without chronic kidney disease: results from the IDEAL trial. Journal of Internal Medicine 2010;267(6):567-75. [MEDLINE: 20141566].
85. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, et al.Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study. American Journal of Cardiology 2004;94(6):720-4. [MEDLINE: 15374773].
86. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, et al.High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.[Erratum appears in JAMA. 2005 Dec 28;294(24):3092]. JAMA 2005;294(19):2437-45. [MEDLINE: 16287954].
87. Imai Y, Suzuki H, Saito T, Tsuji I, Abe K, Saruta T. The effect of pravastatin on renal function and lipid metabolism in patients with renal dysfunction with hypertension and hyperlipidemia. Pravastatin and Renal Function Research Group. Clinical & Experimental Hypertension (New York) 1999;21(8):1345-55. [MEDLINE: 10574417].
88. Glynn RJ, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, et al.A randomized trial of rosuvastatin in the prevention of venous thromboembolism. New England Journal of Medicine 2009;360(18):1851-61. [MEDLINE: 19329822].
89. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, et al.Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New England Journal of Medicine 2008;359(21):2195-207. [MEDLINE: 18997196].
90. Ridker PM, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Khurmi NS, et al.Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. American Journal of Cardiology 2007;100(11):1659-64. [MEDLINE: 18036365].
91. Ridker PM, MacFadyen J, Cressman M, Glynn RJ. Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial. Journal of the American College of Cardiology 2010;55(12):1266-73. [MEDLINE: 20206456].
92. Lam KS, Cheng IK, Janus ED, Pang RW. Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia 1995;38(5):604-9. [MEDLINE: 7489845].
93. Lee TM, Lin MS, Tsai CH, Chang NC. Add-on and withdrawal effect of pravastatin on proteinuria in hypertensive patients treated with AT receptor blockers. Kidney International 2005;68(2):779-87. [MEDLINE: 16014056].
94. Lee TM, Su SF, Tsai CH. Effect of pravastatin on proteinuria in patients with well-controlled hypertension. Hypertension 2002;40(1):67-73. [MEDLINE: 12105140].
95. Lintott CJ, Scott RS, Bremer JM, Shand BI. Fluvastatin for dyslipoproteinemia, with or without concomitant chronic renal insufficiency. American Journal of Cardiology 1995;76(2):97A-101A. [MEDLINE: 7604809].
96. Lemos PA, Serruys PW, de Feyter P, Mercado NF, Goedhart D, Saia F, et al.Long-term fluvastatin reduces the hazardous effect of renal impairment on four-year atherosclerotic outcomes (a LIPS substudy). American Journal of Cardiology 2005;95(4):445-51. [MEDLINE: 15695126].
97. Fassett R, Robertson I, Ball M, Geraghty D, Sharman J, Coombes J. A randomised trial assessing the effects of atorvastatin on arterial stiffness in chronic kidney disease [abstract no: SU193]. World Congress of Nephrology; 2009 May 22-26; Milan, Italy. 2009.
98. Fassett RG, Ball MJ, Robertson IK, Geraghty DP, Coombes JS. Atorvastatin and the progression of chronic kidney disease: the LORD Trial [abstract no: F-PO1919]. Journal of the American Society of Nephrology 2008;19(Abstracts Issue):543A. [CENTRAL: CN-00773725].
99. Fassett RG, Ball MJ, Robertson IK, Geraghty DP, Coombes JS. Baseline serum lipids and renal function in chronic kidney disease patients entering the LORD trial. International Journal of Clinical Pharmacology & Therapeutics 2006;44(11):580-8. [MEDLINE: 17176625].
100. Fassett RG, Ball MJ, Robertson IK, Geraghty DP, Coombes JS. The Lipid lowering and Onset of Renal Disease (LORD) Trial: a randomized double blind placebo controlled trial assessing the effect of atorvastatin on the progression of kidney disease. BMC Nephrology 2008;9:4. [MEDLINE: 18366658].
101. Fassett RG, Coombes JS, Purse LM, Watts M, Chugg KL, Geraghty DP. Enrolment in a clinical trial improves renal function. [abstract no: SU-PO1057]. Journal of the American Society of Nephrology 2003;14(Nov):768A. [CENTRAL: CN-00583896].
102. Fassett RG, Oliver K, Summers MJ, Smith M, Anderson LM, Coombes JS. Lipid lowering therapy and cognitive function in patients with chronic kidney disease [abstract no: PUB623]. Journal of the American Society of Nephrology 2005;16:917A. [CENTRAL: CN-00636136].
103. Fassett RG, Robertson IK, Ball MJ, Geraghty DP, Coombes JS. Effect of atorvastatin on kidney function in chronic kidney disease: a randomised double-blind placebo-controlled trial. Atherosclerosis 2010;213(1):218-24. [MEDLINE: 20810109].
104. Fassett RG, Robertson IK, Ball MJ, Geraghty DP, Sharman JE, Coombes JS. Effects of atorvastatin on arterial stiffness in chronic kidney disease: a randomised controlled trial. Journal of Atherosclerosis & Thrombosis 2010;17(3):235-41. [MEDLINE: 20032570].
105. Fassett RG, Robertson IK, Geraghty DP, Ball MJ, Burton NW, Coombes JS. Physical activity levels in patients with chronic kidney disease entering the LORD trial. Medicine & Science in Sports & Exercise 2009;41(5):985-91. [MEDLINE: 19346990].
106. Fassett RG, Robertson IK, Geraghty DP, Ball MJ, Coombes JS. Dietary intake of patients with chronic kidney disease entering the LORD trial: adjusting for underreporting. Journal of Renal Nutrition 2007;17(4):235-42. [MEDLINE: 17586421].
107. Summers MJ, Oliver KR, Coombes JS, Fassett RG. Effect of atorvastatin on cognitive function in patients from the Lipid Lowering and Onset of Renal Disease (LORD) trial. Pharmacotherapy 2007;27(2):183-90. [MEDLINE: 17253908].
108. Ishikawa T, Mizuno K, Nakaya N, Ohashi Y, Tajima N, Kushiro T, et al.The relationship between the effect of pravastatin and risk factors for coronary heart disease in Japanese patients with hypercholesterolemia. Circulation Journal 2008;72(10):1576-82. [MEDLINE: 18756039].
109. Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study Group. Design and baseline characteristics of a study of primary prevention of coronary events with pravastatin among Japanese with mildly elevated cholesterol levels. Circulation Journal 2004;68(9):860-7. [MEDLINE: 15329509].
110. Mizuno K, Nakaya N, Ohashi Y, Tajima N, Kushiro T, Teramoto T, et al.Usefulness of pravastatin in primary prevention of cardiovascular events in women: analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA study). Circulation 2008;117(4):494-502. [MEDLINE: 18172039].
111. Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, et al.Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 2006;368(9542):1155-63. [MEDLINE: 17011942].
112. Nakamura H, MEGA Study Group. Primary prevention of cardiovascular diseases among hypercholesterolemic Japanese with a low dose of pravastatin. Atherosclerosis Supplements 2007;8(2):13-7. [MEDLINE: 17586102].
113. Nakamura H, Mizuno K, Ohashi Y, Yoshida T, Hirao K, Uchida Y, et al.Pravastatin and cardiovascular risk in moderate chronic kidney disease. Atherosclerosis 2009;206(2):512-7. [MEDLINE: 19423108].
114. Tanaka Y, Matsuyama Y, Ohashi Y, MEGA Study Group. Estimation of treatment effect adjusting for treatment changes using the intensity score method: application to a large primary prevention study for coronary events (MEGA study). Statistics in Medicine 2008;27(10):1718-33. [MEDLINE: 17922525].
115. Teramoto T, Ohashi Y, Nakaya N, Yokoyama S, Mizuno K, Nakamura H, et al.Practical risk prediction tools for coronary heart disease in mild to moderate hypercholesterolemia in Japan: originated from the MEGA study data. Circulation Journal 2008;72(10):1569-75. [MEDLINE: 18762707].
116. Uchiyama S, Nakaya N, Mizuno K, Ohashi Y, Tajima N, Kushiro T, et al.Risk factors for stroke and lipid-lowering effect of pravastatin on the risk of stroke in Japanese patients with hypercholesterolemia: analysis of data from the MEGA Study, a large randomized controlled trial. Journal of the Neurological Sciences 2009;284(1-2):72-6. [MEDLINE: 19423132].
117. Yoshida M, Matsuyama Y, Ohashi Y, MEGA Study Group. Estimation of treatment effect adjusting for dependent censoring using the IPCW method: an application to a large primary prevention study for coronary events (MEGA study). Clinical Trials 2007;4(4):318-28. [MEDLINE: 17848493].
118. Mori Y, Tsuruoka A. Effect of pravastatin on microalbuminuria in patients with non-insulin-dependent diabetes mellitus. Journal of the Japan Diabetes Society 1992;35(3):265-8. [EMBASE: 1992147776].
119. Mori Y, Yokoyama J, Tsuruoka A, Ikeda Y. Effect of pravastatin on microalbuminuria in patients with non-insulin-dependent diabetes mellitus - A randomized control study. Jikeikai Medical Journal 1992;39(4):341-8. [EMBASE: 1993068032].
120. Nakamura T, Ushiyama C, Hirokawa K, Osada S, Inoue T, Shimada N, et al.Effect of cerivastatin on proteinuria and urinary podocytes in patients with chronic glomerulonephritis. Nephrology Dialysis Transplantation 2002;17(5):798-802. [MEDLINE: 11981066].
121. Nakamura T, Sugaya T, Kawagoe Y, Ueda Y, Osada S, Koide H. Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy. Diabetes Care 2005;28(11):2728-32. [MEDLINE: 16249547].
122. Nakamura T, Sugaya T, Kawagoe Y, Suzuki T, Inoue T, Node K. Effect of pitavastatin on urinary liver-type fatty-acid-binding protein in patients with nondiabetic mild chronic kidney disease. American Journal of Nephrology 2006;26(1):82-6. [MEDLINE: 16534182].
123. Nellemann B, Gormsen LC, Dollerup J, Schmitz O, Mogensen CE, Rasmussen LM, et al.Simvastatin reduces plasma osteoprotegerin in type 2 diabetic patients with microalbuminuria. Diabetes Care 2007;30(12):3122-4. [MEDLINE: 17804683].
124. Nielsen S, Schmitz O, Moller N, Porksen N, Klausen IC, Alberti KG, et al.Renal function and insulin sensitivity during simvastatin treatment in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria. Diabetologia 1993;36(10):1079-86. [MEDLINE: 8243858].
125. Rutter MK, Prais HR, Charlton-Menys V, Gittins M, Roberts C, Davies RR, et al.Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high- vs. low-dose atorvastatin(1). Diabetic Medicine 2011;28(1):100-8. [MEDLINE: 21166851].
126. Panichi V, Mantuano E, Paoletti S, Santi S, Manca RG, Cutrupi S, et al.Effect of simvastatin on plasma asymmetric dimethylarginine concentration in patients with chronic kidney disease. Journal of Nephrology 2008;21(1):38-44. [MEDLINE: 18264935].
127. Panichi V, Paoletti S, Manca-Rizza G, Taccola D, Innocenti M, Casto G, et al.Effect of simvastatin therapy on inflammatory markers and lipids in pre-dialysis patients [abstract no: SP167]. Nephrology Dialysis Transplantation 2005;20(Suppl 5):v75. [CENTRAL: CN-00678037].
128. Panichi V, Paoletti S, Mantuano E, Manca-Rizza G, Filippi C, Santi S, et al.In vivo and in vitro effects of simvastatin on inflammatory markers in pre-dialysis patients. Nephrology Dialysis Transplantation 2006;21(2):337-44. [MEDLINE: 16249194].
129. Anonymous. A coronary primary prevention study of Scottish men aged 45-64 years: trial design. The West of Scotland Coronary Prevention Study Group. Journal of Clinical Epidemiology 1992;45(8):849-60. [MEDLINE: 1624967].
130. Anonymous. Baseline risk factors and their association with outcome in the West of Scotland Coronary Prevention Study. The West of Scotland Coronary Prevention Study Group. American Journal of Cardiology 1997;79(6):756-62. [MEDLINE: 9070554].
131. Anonymous. Computerised record linkage: compared with traditional patient follow-up methods in clinical trials and illustrated in a prospective epidemiological study. The West of Scotland Coronary Prevention Study Group. Journal of Clinical Epidemiology 1995;48(12):1441-52. [MEDLINE: 8543958].
132. Anonymous. Design, rational, and baseline characteristics of the Prospective Pravastatin Pooling (PPP) project--a combined analysis of three large-scale randomized trials: Long-term Intervention with Pravastatin in Ischemic Disease (LIPID), Cholesterol and Recurrent Events (CARE), and West of Scotland Coronary Prevention Study (WOSCOPS). American Journal of Cardiology 1995;76(12):899-905. [MEDLINE: 7484829].
133. Anonymous. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998;97(15):1440-5. [MEDLINE: 9576423].
134. Anonymous. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. New England Journal of Medicine 1998;339(19):1349-57. [MEDLINE: 9841303].
135. Anonymous. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. New England Journal of Medicine 1998;339(19):1349-57. [MEDLINE: 9841303].
136. Anonymous. Screening experience and baseline characteristics in the West of Scotland Coronary Prevention Study. The WOSCOPS Study Group. West of Scotland Coronary Prevention Study. American Journal of Cardiology 1995;76(7):485-91. [MEDLINE: 7653449].
137. Anonymous. The effects of pravastatin on hospital admission in hypercholesterolemic middle-aged men: West of Scotland Coronary Prevention Study. Journal of the American College of Cardiology 1999;33(4):909-15. [MEDLINE: 10091815].
138. Anonymous. West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet 1996;348(9038):1339-42. [MEDLINE: 8918276].
139. Batty GD, Wang Y, Brouilette SW, Shiels P, Packard C, Moore J, et al.Socioeconomic status and telomere length: the West of Scotland Coronary Prevention Study. Journal of Epidemiology & Community Health 2009;63(10):839-41. [MEDLINE: 19468018].
140. Brouilette SW, Moore JS, McMahon AD, Thompson JR, Ford I, Shepherd J, et al.Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. Lancet 2007;369(9556):107-14. [MEDLINE: 17223473].
141. Byington RP, Davis BR, Plehn JF, White HD, Baker J, Cobbe SM, et al.Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project. Circulation 2001;103(3):387-92. [MEDLINE: 11157690].
142. Caro J, Klittich W, McGuire A, Ford I, Norrie J, Pettitt D, et al.The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin. BMJ 1997;315(7122):1577-82. [MEDLINE: 9437275].
143. Caro J, Klittich W, McGuire A, Ford I, Pettitt D, Norrie J, et al.International economic analysis of primary prevention of cardiovascular disease with pravastatin in WOSCOPS. West of Scotland Coronary Prevention Study. European Heart Journal 1999;20(4):263-8. [MEDLINE: 10099920].
144. Cui J, Forbes A, Kirby A, Marschner I, Simes J, West M, et al.Parametric conditional frailty models for recurrent cardiovascular events in the lipid study. Clinical Trials 2008;5(6):565-74. [MEDLINE: 19029205].
145. DeFilippis AP, Bansal S, Blumenthal RS. Long-term follow-up of the West of Scotland Coronary Prevention Study. New England Journal of Medicine 2008;358(2):194-5. [MEDLINE: 18193527].
146. Ford I, Murray H, Packard CJ, Shepherd J, MacFarlane PW, Cobbe SM, et al.Long-term follow-up of the West of Scotland Coronary Prevention Study. New England Journal of Medicine 2007;357(15):1477-86. [MEDLINE: 17928595].
147. Freeman DJ, Norrie J, Caslake MJ, Gaw A, Ford I, Lowe GD, et al.C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 2002;51(5):1596-600. [MEDLINE: 11978661].
148. Glasziou PP, Irwig L, Heritier S, Simes RJ, Tonkin A, LIPID Study Investigators. Monitoring cholesterol levels: measurement error or true change?. Annals of Internal Medicine 2008;148(9):656-61. [MEDLINE: 18458278].
149. Hague W, Forder P, Simes J, Hunt D, Tonkin A, LIPID Investigators. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study. American Heart Journal 2003;145(4):643-51. [MEDLINE: 12679760].
150. LIPID Study Group. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up.[Erratum appears in Lancet 2002 Nov 2;360(9343):1430]. Lancet 2002;359(9315):1379-87. [MEDLINE: 11978335].
151. Liakishev AA. Long-term follow-up of the West of Scotland Coronary Prevention Study. Kardiologiia 2007;47(12):65-6. [MEDLINE: 18260982].
152. Lowe G, Rumley A, Norrie J, Ford I, Shepherd J, Cobbe S, et al.Blood rheology, cardiovascular risk factors, and cardiovascular disease: the West of Scotland Coronary Prevention Study.[Erratum appears in Thromb Haemost 2001 May;85(5):946]. Thrombosis & Haemostasis 2000;84(4):553-8. [MEDLINE: 11057849].
153. Macfarlane PW, Norrie J, WOSCOPS Executive Committee. The value of the electrocardiogram in risk assessment in primary prevention: experience from the West of Scotland Coronary Prevention Study. Journal of Electrocardiology 2007;40(1):101-9. [MEDLINE: 17069838].
154. McEvoy JW, Margey R, Blake GJ. Long-term follow-up of the West of Scotland Coronary Prevention Study. New England Journal of Medicine 2008;358(2):193-5. [MEDLINE: 18184967].
155. Nestel PJ, Baghurst K, Colquhoun DM, Simes RJ, Mehalski K, White HD, et al.Relation of diet to cardiovascular disease risk factors in subjects with cardiovascular disease in Australia and New Zealand: analysis of the Long-Term Intervention with Pravastatin in Ischaemic Disease trial. American Journal of Clinical Nutrition 2005;81(6):1322-9. [MEDLINE: 15941882].
156. Packard CJ, O'Reilly DS, Caslake MJ, McMahon AD, Ford I, Cooney J, et al.Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. New England Journal of Medicine 2000;343(16):1148-55. [MEDLINE: 11036120].
157. Pfeffer MA, Keech A, Sacks FM, Cobbe SM, Tonkin A, Byington RP, et al.Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project. Circulation 2002;105(20):2341-6. [MEDLINE: 12021218].
158. Reid IR, Hague W, Emberson J, Baker J, Tonkin A, Hunt D, et al.Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease. Lancet 2001;357(9255):509-12. [MEDLINE: 11229669].
159. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al.The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. New England Journal of Medicine 1996;335(14):1001-9. [MEDLINE: 8801446].
160. Sacks FM, Pfeffer MA, Moye' L, Brown LE, Hamm P, Cole TG, et al.Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events trial (CARE).[erratum appears in Am J Cardiol 1992 Feb 15;69(5):574]. American Journal of Cardiology 1991;68(15):1436-46. [MEDLINE: 1746424].
161. Sacks FM, Tonkin AM, Shepherd J, Braunwald E, Cobbe S, Hawkins CM, et al.Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation 2000;102(16):1893-900. [MEDLINE: 11034935].
162. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM, et al.Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003;108(4):414-9. [MEDLINE: 12860911].
163. Sattar N, Scherbakova O, Ford I, O'Reilly DS, Stanley A, Forrest E, et al.Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study. Diabetes 2004;53(11):2855-60. [MEDLINE: 15504965].
164. Shepherd J. The West of Scotland Coronary Prevention Study: a trial of cholesterol reduction in Scottish men. American Journal of Cardiology 1995;76(9):113C-7C. [MEDLINE: 7572679].
165. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al.Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. New England Journal of Medicine 1995;333(20):1301-7. [MEDLINE: 7566020].
166. Shepherd J, Gaw A, West of Scotland Coronary Prevention Study Group. The anatomy of a clinical trial. The West of Scotland Coronary Prevention Study. Medical Principles & Practice 2002;11 Suppl 2:17-30. [MEDLINE: 12444307].
167. Simes J, Furberg CD, Braunwald E, Davis BR, Ford I, Tonkin A, et al.Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project. European Heart Journal 2002;23(3):207-15. [MEDLINE: 11792135].
168. Simes RJ. Prospective meta-analysis of cholesterol-lowering studies: the Prospective Pravastatin Pooling (PPP) Project and the Cholesterol Treatment Trialists (CTT) Collaboration. American Journal of Cardiology 1995;76(9):122C-6C. [MEDLINE: 7572681].
169. Soderberg S, Colquhoun D, Keech A, Yallop J, Barnes EH, Pollicino C, et al.Leptin, but not adiponectin, is a predictor of recurrent cardiovascular events in men: results from the LIPID study. International Journal of Obesity 2009;33(1):123-30. [MEDLINE: 19050671].
170. Stewart RA, North FM, Sharples KJ, Simes RJ, Tonkin AM, White HD, et al.Differences in cardiovascular mortality between Australia and New Zealand according to socioeconomic status: findings from the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study. New Zealand Medical Journal 2008;121(1269):11-23. [MEDLINE: 18278078].
171. Stewart RA, North FM, West TM, Sharples KJ, Simes RJ, Colquhoun DM, et al.Depression and cardiovascular morbidity and mortality: cause or consequence?. European Heart Journal 2003;24(22):2027-37. [MEDLINE: 14613739].
172. Stewart RA, Sharples KJ, North FM, Menkes DB, Baker J, Simes J. Long-term assessment of psychological well-being in a randomized placebo-controlled trial of cholesterol reduction with pravastatin. The LIPID Study Investigators. Archives of Internal Medicine 2000;160(20):3144-52. [MEDLINE: 11074745].
173. Streja L, Packard CJ, Shepherd J, Cobbe S, Ford I, WOSCOPS Group. Factors affecting low-density lipoprotein and high-density lipoprotein cholesterol response to pravastatin in the West Of Scotland Coronary Prevention Study (WOSCOPS). American Journal of Cardiology 2002;90(7):731-6. [MEDLINE: 12356386].
174. Tonelli M, Isles C, Craven T, Tonkin A, Pfeffer MA, Shepherd J, et al.Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation 2005;112(2):171-8. [MEDLINE: 15998677].
175. Tonelli M, Isles C, Curhan GC, Tonkin A, Pfeffer MA, Shepherd J, et al.Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 2004;110(12):1557-63. [MEDLINE: 15364796].
176. Tonelli M, Jose P, Curhan G, Sacks F, Braunwald E, Pfeffer M, et al.Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial. BMJ 2006;332(7555):1426. [MEDLINE: 16714328].
177. Tonelli M, Keech A, Shepherd J, Sacks F, Tonkin A, Packard C, et al.Effect of pravastatin in people with diabetes and chronic kidney disease. Journal of the American Society of Nephrology 2005;16(12):3748-54. [MEDLINE: 16251235].
178. Tonelli M, Moye L, Sacks F, Coles T, Curhan G. Effect of pravastatin on loss of renal function in patients with CKD [abstract no: F-P0996]. Journal of the American Society of Nephrology 2002;13(September, Program & Abstracts):257A-8A. [CENTRAL: CN-00448025].
179. Tonelli M, Moye L, Sacks F, Curhan G. Pravastatin is effective for secondary prevention of cardiovascular events in patients with chronic renal insufficiency (CRI) [abstract]. Journal of the American Society of Nephrology 2001;12(Program & Abstracts):252A. [CENTRAL: CN-00448024].
180. Tonelli M, Moye L, Sacks FM, Cole T, Curhan GC, Cholesterol and Recurrent Events Trial Investigators. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. Journal of the American Society of Nephrology 2003;14(6):1605-13. [MEDLINE: 12761262].
181. Tonelli M, Moye L, Sacks FM, Kiberd B, Curhan G, Cholesterol and Recurrent Events (CARE) Trial Investigators. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Annals of Internal Medicine 2003;138(2):98-104. [MEDLINE: 12529091].
182. Tonelli M, Sacks F, Pfeffer M, Jhangri GS, Curhan G, Cholesterol and Recurrent Events (CARE) Trial Investigators. Biomarkers of inflammation and progression of chronic kidney disease. Kidney International 2005;68(1):237-45. [MEDLINE: 15954913].
183. Tonelli M, Sacks F, Pfeffer M, Lopez-Jimenez F, Jhangri GS, Curhan G. Effect of pravastatin on blood pressure in people with cardiovascular disease. Journal of Human Hypertension 2006;20(8):560-5. [MEDLINE: 16625234].
184. Tsubokura M, Kami M. Long-term follow-up of the West of Scotland Coronary Prevention Study. New England Journal of Medicine 2008;358(2):193-4. [MEDLINE: 18193526].
185. Wallace AM, McMahon AD, Packard CJ, Kelly A, Shepherd J, Gaw A, et al.Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation 2001;104(25):3052-6. [MEDLINE: 11748099].
186. West MJ, Nestel PJ, Kirby AC, Schnabel R, Sullivan D, Simes RJ, et al.The value of N-terminal fragment of brain natriuretic peptide and tissue inhibitor of metalloproteinase-1 levels as predictors of cardiovascular outcome in the LIPID study. European Heart Journal 2008;29(7):923-31. [MEDLINE: 18296678].
187. West MJ, White HD, Simes RJ, Kirby A, Watson JD, Anderson NE, et al.Risk factors for non-haemorrhagic stroke in patients with coronary heart disease and the effect of lipid-modifying therapy with pravastatin. Journal of Hypertension 2002;20(12):2513-7. [MEDLINE: 12473877].
188. White HD, Simes RJ, Anderson NE, Hankey GJ, Watson JD, Hunt D, et al.Pravastatin therapy and the risk of stroke. New England Journal of Medicine 2000;343(5):317-26. [MEDLINE: 10922421].
189. Zito F, Lowe GD, Rumley A, McMahon AD, Humphries SE, WOSCOPS Study Group West of Scotland Coronary Prevention Study. Association of the factor XII 46C>T polymorphism with risk of coronary heart disease (CHD) in the WOSCOPS study. Atherosclerosis 2002;165(1):153-8. [MEDLINE: 12208481].
190. Asselbergs FW, Diercks GF, Hillege HL, van Boven AJ, Janssen WM, Voors AA, et al.Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004;110(18):2809-16. [MEDLINE: 15492322].
191. Asselbergs FW, van Roon AM, Hillege HL, de Jong PE, Gans RO, Smit AJ, et al.Effects of fosinopril and pravastatin on carotid intima-media thickness in subjects with increased albuminuria. Stroke 2005;36(3):649-53. [MEDLINE: 15692120].
192. Asselbergs FW, van der Harst P, van Roon AM, Hillege HL, de Jong PE, Gans RO, et al.Long-term effects of pravastatin and fosinopril on peripheral endothelial function in albuminuric subjects. Atherosclerosis 2008;196(1):349-55. [MEDLINE: 17141245].
193. Atthobari J, Asselbergs FW, Boersma C, de VR, Hillege HL, van Gilst WH, et al.Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT). Clinical Therapeutics 2006;28(3):432-44. [MEDLINE: 16750458].
194. Atthobari J, Asselbergs FW, Boersma C, de Vries R, Hillege HL, van Gilst WH, et al.Cost-effectiveness of screening for albuminuria and subsequent treatment with an ACE-inhibitor; a pharmaco-economic analysis [abstract no: TH-FC169]. Journal of the American Society of Nephrology 2005;16:36A. [CENTRAL: CN-00583782].
195. Atthobari J, Brantsma AH, Gansevoort RT, Visser ST, Asselbergs FW, van Gilst WH, et al.The effect of statins on urinary albumin excretion (UAE) and glomerular filtration rate (GFR): a randomized controlled trial (RCT) and observational cohort study [abstract no: F-FC151]. Journal of the American Society of Nephrology 2005;16:71A. [CENTRAL: CN-00583784].
196. Atthobari J, Brantsma AH, Gansevoort RT, Visser ST, Asselbergs FW, van Gilst WH, et al.The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study. Nephrology Dialysis Transplantation 2006;21(11):3106-14. [MEDLINE: 16720593].
197. Bello AK, de Zeeuw D, El Nahas M, Brantsma AH, Bakker SJ, de Jong PE, et al.Impact of weight change on albuminuria in the general population. Nephrology Dialysis Transplantation 2007;22(6):1619-27. [MEDLINE: 17360767].
198. Brouwers FP, Asselbergs FW, Hillege HL, de Boer RA, Gansevoort RT, van Veldhuisen DJ, et al.Long-term effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria: ten years of follow-up of Prevention of Renal and Vascular End-stage Disease Intervention Trial (PREVEND IT). American Heart Journal 2011;161(6):1171-8. [MEDLINE: 21641365].
199. Diercks GF, Janssen WM, van Boven AJ, Bak AA, de Jong PE, Crijns HJ, et al.Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria (the Prevention of REnal and Vascular ENdstage Disease Intervention Trial [PREVEND IT]). American Journal of Cardiology 2000;86(6):635-8. [MEDLINE: 10980214].
200. Geluk CA, Asselbergs FW, Hillege HL, Bakker SJ, de Jong PE, Zijlstra F, et al.Impact of statins in microalbuminuric subjects with the metabolic syndrome: a substudy of the PREVEND Intervention Trial. European Heart Journal 2005;26(13):1314-20. [MEDLINE: 15820998].
201. van de Wal RM, Gansevoort RT, van der Harst P, Boomsma F, Thijs Plokker HW, van Veldhuisen DJ, et al.Predictors of angiotensin-converting enzyme inhibitor-induced reduction of urinary albumin excretion in nondiabetic patients. Hypertension 2006;48(5):870-6. [MEDLINE: 17000930].
202. van de Wal RM, van der Harst P, Gerritsen WB, van der Horst F, Plokker TH, Gansevoort RT, et al.Plasma matrix metalloproteinase-9 and ACE-inhibitor-induced improvement of urinary albumin excretion in non-diabetic, microalbuminuric subjects. Journal of the Renin-Angiotensin-Aldosterone System 2007;8(4):177-80. [MEDLINE: 18205096].
203. van der Harst P, Asselbergs FW, Hillege HL, Voors AA, van Veldhuisen DJ, van Gilst WH, et al.Effect of fosinopril treatment on serum C-reactive protein levels in patients with microalbuminuria. American Journal of Cardiology 2008;102(2):223-5. [MEDLINE: 18602526].
204. Rayner BL, Byrne M, van Zyl-Smit R. Treatment of hyperlipidaemia with simvastatin (SV) and diet, vs diet alone in idiopathic membranous nephropathy (IMN) [abstract]. Nephrology Dialysis Transplantation 1994;9(7):963. [CENTRAL: CN-00261011].
205. Rayner BL, Byrne MJ, van Zyl-Smit R. A prospective clinical trial comparing the treatment of idiopathic membranous nephropathy and nephrotic syndrome with simvastatin and diet, versus diet alone. Clinical Nephrology 1996;46(4):219-24. [MEDLINE: 8905205].
206. Renke M, Tylicki L, Rutkowski P, Neuwelt A, Larczynski W, Zietkiewicz M, et al.Atorvastatin improves tubular status in non-diabetic patients with chronic kidney disease - placebo controlled, randomized, cross-over study. Acta Biochimica Polonica 2010;57(4):547-52. [MEDLINE: 21079818].
207. Alaupovic P, Attman PO, Knight-Gibson C, Mulec H, Weiss L, Samuelsson O. Effect of fluvastatin on apolipoprotein-defined lipoprotein subclasses in patients with chronic renal insufficiency. Kidney International 2006;69(10):1865-71. [MEDLINE: 16572113].
208. Samuelsson O, Attman PO, Knight-Gibson C, Mulec H, Weiss L, Alaupovic P. Fluvastatin improves lipid abnormalities in patients with moderate to advanced chronic renal insufficiency. American Journal of Kidney Diseases 2002;39(1):67-75. [MEDLINE: 11774104].
209. Sawara Y, Takei T, Uchida K, Ogawa T, Yoshida T, Tsuchiya K, et al.Effects of lipid-lowering therapy with rosuvastatin on atherosclerotic burden in patients with chronic kidney disease. Internal Medicine 2008;47(17):1505-10. [MEDLINE: 18758125].
210. Sawara Y, Takei T, Uchida K, Tsuchiya K, Nitta K. Effects of lipid-lowering therapy with rosuvastatin on atherosclerotic burden in patients with chronic kidney disease [abstract no: SA166]. World Congress of Nephrology; 2009 May 22-26; Milan, Italy. 2009.
211. Scanferla F, Toffoletto PP, Roncali D, Bazzato G. Associated effect of hepatic hydroxymethylglutaryl coenzyme A reductase + angiotensin converting enzyme inhibitors on the progression of renal failure in hypertensive subjects. American Journal of Hypertension 1991;4(10 Pt 1):868-74. [MEDLINE: 1747221].
212. Baigent C, Landray M. Study of Heart and Renal Protection (SHARP): Does lowering cholesterol prevent major vascular events in patients with chronic kidney disease? Final Protocol (Version 5: 12th July 2005). http://www.ctsu.ox.ac.uk/~sharp/download_protocol_en_v5.pdf (accessed 28 April 2014).
213. Baigent C, Landray M, Reith C, Emberson J, Wheeler DC, Tomson CR, et al.The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011;377(9784):2181-92.
214. Baigent C, Landry M. Study of Heart and Renal Protection (SHARP). Kidney International - Supplement 2003;63(84):S207-10. [MEDLINE: 12694346].
215. SHARP Collaborative Group. SHARP: an international randomized placebo-controlled trial of lipid-lowering in chronic kidney disease. 1-year safety and efficacy experience [abstract no: SU-PO1044]. Journal of the American Society of Nephrology 2007;18(Abstracts Issue):817A. [CENTRAL: CN-00691495].
216. Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9, 438 patients with chronic kidney disease. American Heart Journal 2010;160(5):785-94. [MEDLINE: 21095263].
217. Holmberg B, Brannstrom M, Bucht B, Crougneau V, Dimeny E, Ekspong A, et al.Safety and efficacy of atorvastatin in patients with severe renal dysfunction. Scandinavian Journal of Urology & Nephrology 2005;39(6):503-10. [MEDLINE: 16303728].
218. Stegmayr BG, Brannstrom M, Bucht S, Crougneau V, Dimeny E, Ekspong A, et al.Low-dose atorvastatin in severe chronic kidney disease patients: A randomized, controlled endpoint study. Scandinavian Journal of Urology & Nephrology 2005;39(6):489-97. [MEDLINE: 2005547034].
219. Stegmayr BG, Brannstrom M, Bucht S, Dimeny E, Ekspong A, Granroth B, et al.Safety and efficacy of atorvastatin in patients with impaired renal function [abstract]. 38th Congress. European Renal Association. European Dialysis and Transplantation Association; 2001 Jun 24-27; Vienna, Austria. 2001:134. [CENTRAL: CN-00447841].
220. Stegmayr BG, Nasstrom BG, Brannstrom M, Bucht S, Dimeny E, Gosch J, et al.Safety and efficacy of atorvastatin in patients with severe renal dysfunction [abstract no: A0828]. Journal of the American Society of Nephrology 1998;9(Program & Abstracts):161A. [CENTRAL: CN-00447842].
221. Stegmayr BG, Nasstrom BG, Brannstrom M, Bucht S, Dimeny E, Granroth B, et al.Safety and efficacy of atorvastatin in patients with severe renal dysfunction [abstract no: A1356]. Journal of the American Society of Nephrology 1999;10(Program & Abstracts):268A. [CENTRAL: CN-00583406].
222. Thomas ME, Harris KP, Ramaswamy C, Hattersley JM, Wheeler DC, Varghese Z, et al.Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria. Kidney International 1993;44(5):1124-9. [MEDLINE: 8264145].
223. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, et al.HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. New England Journal of Medicine 2007;357(13):1301-10. [MEDLINE: 17898099].
224. Deedwania P, Barter P, Carmena R, Fruchart JC, Grundy SM, Haffner S, et al.Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet 2006;368(9539):919-28. [MEDLINE: 16962881].
225. Johnson C, Waters DD, DeMicco DA, Breazna A, Bittner V, Greten H, et al.Comparison of effectiveness of atorvastatin 10 mg versus 80 mg in reducing major cardiovascular events and repeat revascularization in patients with previous percutaneous coronary intervention (post hoc analysis of the Treating to New Targets [TNT] Study). American Journal of Cardiology 2008;102(10):1312-7. [MEDLINE: 18993147].
226. Kastelein JJ, van der Steeg WA, Holme I, Gaffney M, Cater NB, Barter P, et al.Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation 2008;117(23):3002-9. [MEDLINE: 18519851].
227. Khush KK, Waters DD, Bittner V, Deedwania PC, Kastelein JJ, Lewis SJ, et al.Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study. Circulation 2007;115(5):576-83. [MEDLINE: 17261662].
228. Kostis JB, Breazna A, Deedwania PC, LaRosa JC, Treating to New Targets Steering Committee and Investigators. The benefits of intensive lipid lowering in patients with stable coronary heart disease with normal or high systolic blood pressure: an analysis of the Treating to New Targets (TNT) study. Journal of Clinical Hypertension 2008;10(5):367-76. [MEDLINE: 18453796].
229. LaRosa JC, Grundy SM, Kastelein JJ, Kostis JB, Greten H, Treating to New Targets (TNT) Steering Committee and Investigators. Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study). American Journal of Cardiology 2007;100(5):747-52. [MEDLINE: 17719314].
230. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al.Intensive lipid lowering with atorvastatin in patients with stable coronary disease. New England Journal of Medicine 2005;352(14):1425-35. [MEDLINE: 15755765].
231. Mark DB, Knight JD, Cowper PA, Davidson-Ray L, Anstrom KJ. Long-term economic outcomes associated with intensive versus moderate lipid-lowering therapy in coronary artery disease: results from the Treating to New Targets (TNT) Trial. American Heart Journal 2008;156(4):698-705. [MEDLINE: 18926150].
232. Shah SJ, Waters DD, Barter P, Kastelein JJ, Shepherd J, Wenger NK, et al.Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery. Journal of the American College of Cardiology 2008;51(20):1938-43. [MEDLINE: 18482661].
233. Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S, et al.Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 2006;29(6):1220-6. [MEDLINE: 16731999].
234. Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, et al.Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clinical Journal of The American Society of Nephrology: CJASN 2007;2(6):1131-9. [MEDLINE: 17942759].
235. Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, et al.Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. Journal of the American College of Cardiology 2008;51(15):1448-54. [MEDLINE: 18402899].
236. Shepherd J, Kastelein JP, Bittner VA, Carmena R, Deedwania PC, Breazna A, et al.Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease. Mayo Clinic Proceedings 2008;83(8):870-9. [MEDLINE: 18674471].
237. Shepherd J, Wenger NK. Intensive lipid lowering with atorvastatin is associated with significant cardiovascular benefits in patients with and without chronic kidney disease: the Treating to New Targets (TNT) study [abstract no: SA-PO1121]. Journal of the American Society of Nephrology 2006;17(Abstracts):809A. [CENTRAL: CN-00653729].
238. Shepherd J, Wu C, Zuckerman AL, Wilson DJ, The TNT Steering Committee. Serum uric acid as a predictor of cardiovascular risk: the treating to new targets (TNT) study [abstract no: F-PO1955]. Journal of the American Society of Nephrology 2008;19(Abstracts Issue):552A. [CENTRAL: CN-00776228].
239. Shepherd J, Wun C, Wilson DJ, Zuckerman AL. On-treatment changes in estimated GFR predict response to atorvastatin in patients with coronary heart disease: the treating to new targets (TNT) study [abstract no: TH-PO872]. Journal of the American Society of Nephrology 2008;19(Abstracts Issue):306A. [CENTRAL: CN-00775650].
240. Shepherd J, Wun C, Zuckerman AL, Wilson DJ, The TNT Steering Committee. High dose atorvastatin reduces serum uric acid: a post-hoc analysis of the Treating to New Targets (TNT) study [abstract no: PUB512]. Journal of the American Society of Nephrology 2008;19(Abstracts Issue):926A. [CENTRAL: CN-00775061].
241. Waters DD. Clinical insights from the Treating to New Targets trial. Progress in Cardiovascular Diseases 2009;51(6):487-502. [MEDLINE: 19410683].
242. Waters DD, Guyton JR, Herrington DM, McGowan MP, Wenger NK, Shear C, et al.Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?. American Journal of Cardiology 2004;93(2):154-8. [MEDLINE: 14715339].
243. Waters DD, LaRosa JC, Barter P, Fruchart JC, Gotto AM, Carter R, et al.Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study. Journal of the American College of Cardiology 2006;48(9):1793-9. [MEDLINE: 17084252].
244. Wenger NK, Lewis SJ, Welty FK, Herrington DM, Bittner V, TNT Steering Committee and Investigators. Beneficial effects of aggressive low-density lipoprotein cholesterol lowering in women with stable coronary heart disease in the Treating to New Targets (TNT) study. Heart 2008;94(4):434-9. [MEDLINE: 18070940].
245. Tokunaga M, Tamura M, Kabashima N, Serino R, Shibata T, Matsumoto M, et al.Beneficial effects of pitavastatin on albuminuria and renal function in essential hypertensive patients with chronic kidney disease [abstract no: TH-PO875]. Journal of the American Society of Nephrology 2008;19(Abstracts Issue):307A. [CENTRAL: CN-00773767].
246. Tonolo G, Ciccarese M, Brizzi P, Puddu L, Secchi G, Calvia P, et al.Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment. Diabetes Care 1997;20(12):1891-5. [MEDLINE: 9405913].
247. Baigent C, Landray M, Leaper C, Altmann P, Armitage J, Baxter A, et al.First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. American Journal of Kidney Diseases 2005;45(3):473-84. [MEDLINE: 15754269].
248. Baigent C, UK-HARP Steering Committee. Efficacy and safety of simvastatin and safety of low-dose aspirin among patients with chronic kidney disease: final results of the first UK-heart and renal protection (UK-HARP-I) study [abstract]. Journal of the American Society of Nephrology 2002;13(Program & Abstracts):437A. [CENTRAL: CN-00444305].
249. Verma A, Gordon N, Ranganna KM, Reddy RS, Verma M. Rosuvastatin reduces high sensitivity-C reactive protein and the decline in renal function in hyperlipidemic patients with chronic kidney disease. [abstract no: SA-PO134]. Journal of the American Society of Nephrology 2004;15(Oct):329A. [CENTRAL: CN-00583418].
250. Verma A, Ranganna KM, Reddy RS, Verma M, Gordon NF. Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease. American Journal of Cardiology 2005;96(9):1290-2. [MEDLINE: 16253600].
251. Yasuda G, Kuji T, Hasegawa K, Ogawa N, Shimura G, Ando D, et al.Safety and efficacy of fluvastatin in hyperlipidemic patients with chronic renal disease. Renal Failure 2004;26(4):411-8. [MEDLINE: 15462110].
252. Zhang A, Vertommen J, Van Gaal L, De Leeuw I. Effects of pravastatin on lipid levels, in vitro oxidizability of non-HDL lipoproteins and microalbuminuria in IDDM patients. Diabetes Research & Clinical Practice 1995;29(3):189-94. [MEDLINE: 8591712].
253. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).[erratum appears in JAMA 2003 Jan 8;289(2):178]. JAMA 2002;288(23):2981-97. [MEDLINE: 12479763].
254. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002;288(23):2998-3007. [MEDLINE: 12479764].
255. Anonymous. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.[erratum appears in JAMA 2002 Dec 18;288(23):2976]. JAMA 2000;283(15):1967-75. [MEDLINE: 10789664].
256. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension 2003;42(3):239-46. [MEDLINE: 12925554].
257. Barzilay JI, Davis BR, Cutler JA, Pressel SL, Whelton PK, Basile J, et al.Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Archives of Internal Medicine 2006;166(20):2191-201. [MEDLINE: 17101936].
258. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, et al.Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Journal of Clinical Hypertension 2002;4(6):393-404. [MEDLINE: 12461301].
259. Davis BR, Cutler JA, Furberg CD, Wright JT, Farber MA, Felicetta JV, et al.Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial. Annals of Internal Medicine 2002;137(5 Pt 1):313-20. [MEDLINE: 12204014].
260. Davis BR, Cutler JA, Gordon DJ, Furberg CD, Wright JT, Cushman WC, et al.Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group. American Journal of Hypertension 1996;9(4 Pt 1):342-60. [MEDLINE: 8722437].
261. Leenen FH, Nwachuku CE, Black HR, Cushman WC, Davis BR, Simpson LM, et al.Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension 2006;48(3):374-84. [MEDLINE: 16864749].
262. Lynch AI, Boerwinkle E, Davis BR, Ford CE, Eckfeldt JH, Leiendecker-Foster C, et al.Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study. Pharmacogenetics & Genomics 2009;19(6):415-21. [MEDLINE: 19352213].
263. Rahman M, Baimbridge C, Davis BR, Barzilay J, Basile JN, Henriquez MA, et al.Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). American Journal of Kidney Diseases 2008;52(3):412-24. [MEDLINE: 18676075].
264. Rahman M, Barzilay J, Batuman V, Davis B, Farber M, Henriquez M, et al.Incidence of end stage renal disease (ESRD) and cardiovascular disease (CVD) in high risk hypertensive patients with reduced glomerular filtration rate (GFR) [abstract no: SU-PO641]. Journal of the American Society of Nephrology 2003;14(Nov):674A. [CENTRAL: CN-00583415].
265. Rahman M, Brown CD, Coresh J, Davis BR, Eckfeldt JH, Kopyt N, et al.The prevalence of reduced glomerular filtration rate in older hypertensive patients and its association with cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Archives of Internal Medicine 2004;164(9):969-76. [MEDLINE: 15136305].
266. Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT, Whelton PK, et al.Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. Annals of Internal Medicine 2006;144(3):172-80. [MEDLINE: 16461961].
267. Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT, Whelton PK, et al.Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Archives of Internal Medicine 2005;165(8):936-46. [MEDLINE: 15851647].
268. Rhaman M, Huml A, Baimbridge C, Davis B, Barzilay J, Basile J, et al.Cardiovascular outcomes by glomerular filtration rate in moderately dyslipidemic, hypertensive patients randomized to pravastatin vs usual care: a report from ALLHAT [abstract no: TH-PO891]. Journal of the American Society of Nephrology 2008;19(Abstracts Issue):310A. [CENTRAL: CN-00773854].
269. Wright JT, Harris-Haywood S, Pressel S, Barzilay J, Baimbridge C, Bareis CJ, et al.Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Archives of Internal Medicine 2008;168(2):207-17. [MEDLINE: 18227370].
270. Wright JT, Probstfield JL, Cushman WC, Pressel SL, Cutler JA, Davis BR, et al.ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Archives of Internal Medicine 2009;169(9):832-42. [MEDLINE: 19433694].
271. Nanayakkara PW, Kiefte-De Jong JC, Stehouwer CD, van Ittersum FJ, Olthof MR, Kok RM, et al.Association between global leukocyte DNA methylation, renal function, carotid intima-media thickness and plasma homocysteine in patients with stage 2-4 chronic kidney disease. Nephrology Dialysis Transplantation 2008;23(8):2586-92. [MEDLINE: 18287179].
272. Nanayakkara PW, Kiefte-de Jong JC, ter Wee PM, Stehouwer CD, van Ittersum FJ, Olthof MR, et al.Randomized placebo-controlled trial assessing a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on plasma asymmetric dimethylarginine concentration in mild to moderate CKD. American Journal of Kidney Diseases 2009;53(1):41-50. [MEDLINE: 18786751].
273. Nanayakkara PW, Teerlink T, Stehouwer CD, Allajar D, Spijkerman A, Schalkwijk C, et al.Plasma asymmetric dimethylarginine (ADMA) concentration is independently associated with carotid intima-media thickness and plasma soluble vascular cell adhesion molecule-1 (sVCAM-1) concentration in patients with mild-to-moderate renal failure. Kidney International 2005;68(5):2230-6. [MEDLINE: 16221223].
274. Nanayakkara PW, Van Guldener C, ter Wee PM, Scheffer PG, van Ittersum FJ, Twisk JW, et al.Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on carotid intima-media thickness, endothelial function, and renal function in patients with mild to moderate chronic kidney disease: results from the Anti-Oxidant Therapy in Chronic Renal Insufficiency (ATIC) Study. Archives of Internal Medicine 2007;167(12):1262-70. [MEDLINE: 17592099].
275. Nanayakkara PW, van Guldener C, van Ittersum F, Stehouwer CD, Ter Wee PM. Effect of an oxidative-stress-reducing strategy on carotid intima-media thickness, endothelial function and renal function in patients with mild-to-moderate chronic kidney disease [abstract no: F-PO145]. Journal of the American Society of Nephrology 2006;17(Abstracts):367A. [CENTRAL: CN-00602094].
276. Nanayakkara PW, van Ittersum FJ, Fouque D, Charrie A, Stehouwer CD, Ter Wee PM. Plasma adiponectin is inversely associated with renal function in patients with Stage 3 and 4 chronic kidney disease [abstract no: F-PO146]. Journal of the American Society of Nephrology 2006;17(Abstracts):367A. [CENTRAL: CN-00602093].
277. Fellstrom B, Holdaas H, Jardine AG, Rose H, Schmieder R, Wilpshaar W, et al.Effect of rosuvastatin on outcomes in chronic haemodialysis patients: baseline data from the AURORA study. Kidney & Blood Pressure Research 2007;30(5):314-22. [MEDLINE: 17671394].
278. Fellstrom B, Holdaas H, Jardine AG, Schmieder RE, Holme I, Zannad F. Normalisation of CRP and LDL-C levels is related to reduction of cardiovascular morbidity and mortality in haemodialysis patients on rosuvastatin treatment - a posthoc analysis of the AURORA trial [abstract no: TH-PO472]. Journal of the American Society of Nephrology 2010;21:218A. [CENTRAL: CN-00775607].
279. Fellstrom B, Jardine AG, Holdaas H, Schmieder R, Gottlow M, Johnsson E, et al.Effect of rosuvastatin versus placebo on cardiovascular outcomes in patients with end-stage renal disease on hemodialysis - results of the Aurora Study [abstract no: SA761]. World Congress of Nephrology; 2009 May 22-26; Milan, Italy. 2009.
280. Fellstrom B, Zannad F, Schmieder R, Holdaas H, Jardine A, Armstrong J, et al.A study to evaluate the use of rosuvastatin in subjects on regular haemodialysis: an assessment of survival and cardiovascular events - the AURORA study [abstract no: W520]. Nephrology Dialysis Transplantation 2003;18(Suppl 4):713. [CENTRAL: CN-00509186].
281. Fellstrom B, Zannad F, Schmieder R, Holdaas H, Jardine A, Rose H, et al.Effect of rosuvastatin on outcomes in chronic haemodialysis patients - design and rationale of the AURORA study. Current Controlled Trials in Cardiovascular Medicine 2005;6:8. [EMBASE: 2005487466].
282. Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et al.Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.[Erratum appears in N Engl J Med. 2010 Apr 15;362(15):1450]. New England Journal of Medicine 2009;360(14):1395-407. [MEDLINE: 19332456].
283. Holdaas H, Fellstrom B, Holme I, Schmieder RE, Zannad F, Jardine AG. Rosuvastatin and LDL cholesterol in diabetic patients receiving hemodialysis - a posthoc analysis of the AURORA trial [abstract no:TH-FC049]. Journal of the American Society of Nephrology 2010;21:12A. [CENTRAL: CN-00776147].
284. Holdaas H, Holme I, Schmieder RE, Jardine AG, Zannad F, Norby GE, et al.Rosuvastatin in diabetic hemodialysis patients. Journal of the American Society of Nephrology 2011;22(7):1335-41. [MEDLINE: 21566054].
285. Holdaas H, Jardine AG, Schmieder R, Gottlow M, Johnsson E, Zannad F, et al.Effect of rosuvastatin on cardiovascular outcomes in diabetic patients receiving hemodialysis - results from the Aurora Study [abstract no: SA762]. World Congress of Nephrology; 2009 May 22-26; Milan, Italy. 2009.
286. Jardine AG, Fellstrom B, Holdaas H, Gottlow M, Johnsson E, Zannad F, et al.Risk factors for cardiovascular events in patients receiving haemodialysis - post hoc analyses of the AURORA study [abstract no: SA763]. World Congress of Nephrology; 2009 May 22-26; Milan, Italy. 2009.
287. Dalla Nora E, Passaro A, Zamboni PF, Calzoni F, Fellin R, Solini A. Atorvastatin improves metabolic control and endothelial function in type 2 diabetic patients: a placebo-controlled study. Journal of Endocrinological Investigation 2003;26(1):73-8. [MEDLINE: 12602538].
288. David S, Kumpers P, Haller H, Fliser D. Circulating angiopoietin-2 levels are elevated in hypertensive patients but not influenced by treatment with angiotensin II receptor blocker and statin [abstract no: SA-PO2288]. Journal of the American Society of Nephrology 2008;19(Abstracts Issue):626A. [CENTRAL: CN-00773907].
289. Deighan CJ, Caslake MJ, McConnell M, Boulton-Jones JM, Packard CJ. Comparative effects of cerivastatin and fenofibrate on the atherogenic lipoprotein phenotype in proteinuric renal disease. Journal of the American Society of Nephrology 2001;12(2):341-8. [MEDLINE: 11158224].
290. Dogra GK, Watts GF, Chan DC, Stanton K. Statin therapy improves brachial artery vasodilator function in patients with Type 1 diabetes and microalbuminuria. Diabetic Medicine 2005;22(3):239-42. [MEDLINE: 15717868].
291. Dogra G, Irish A, Chan D, Watts G. A randomized trial of the effect of statin and fibrate therapy on arterial function in CKD. American Journal of Kidney Diseases 2007;49(6):776-85. [MEDLINE: 17533020].
292. Dogra S, Kanganas C, Chan D, Irish A, Watts G. Effect of statin and fibrate therapy on vascular function in chronic kidney disease (CKD) [abstract no: 160]. Nephrology 2005;10(Suppl 3):A422. [CENTRAL: CN-00774612].
293. Dyadyk O, Bagriy A, Kholopov L. Atorvastatin in chronic renal disease with mild to moderate renal failure: 20 months prospective cross-over follow-up [abstract no: SP259]. Nephrology Dialysis Transplantation 2006;21(Suppl 4):iv101. [CENTRAL: CN-00773726].
294. Garcia-de-la-Puente S, Arredondo-Garcia JL, Gutierrez-Castrellon P, Bojorquez-Ochoa A, Maya ER, Perez-Martinez MP. Efficacy of simvastatin in children with hyperlipidemia secondary to kidney disorders. Pediatric Nephrology 2009;24(6):1205-10. [MEDLINE: 19238452].
295. Golper TA, Illingworth DR, Bennett WM. Correction of nephrotic hypercholesterolemia with the HMG-CoA reductase inhibitor lovastatin [abstract]. 10th International Congress of Nephrology; 1987 Jul 26-31; London, UK. 1987:64. [CENTRAL: CN-00583909].
296. Golper TA, Illingworth DR, Bennett WM. Effective and safe short term improvement in nephrotic hypercholesterolemia with the HMG CO-A reductase inhibitor mevinolin [abstract]. Kidney International 1987;31(1):200. [CENTRAL: CN-00774455].
297. Golper TA, Illingworth DR, Morris CD, Bennett WM. Lovastatin in the treatment of multifactorial hyperlipidemia associated with proteinuria. American Journal of Kidney Diseases 1989;13(4):312-20. [MEDLINE: 2650539].
298. Kano K, Nishikura K, Yamada Y, Arisaka O. Effect of fluvastatin and dipyridamole on proteinuria and renal function in childhood IGA nephropathy with mild histological findings and moderate proteinuria [abstract no: T756-757]. Nephrology Dialysis Transplantation 2003;18(Suppl 4):524-5.
299. Kano K, Nishikura K, Yamada Y, Arisaka O. Effect of fluvastatin and dipyridamole on proteinuria and renal function in childhood IgA nephropathy with mild histological findings and moderate proteinuria. Clinical Nephrology 2003;60(2):85-9. [MEDLINE: 12940609].
300. Kano K, Nishikura K, Yamada Y, Arisaka O. Effect of fluvastatin on proteinuria [abstract no: M-PO20068]. Nephrology 2005;10(Suppl):A33. [CENTRAL: CN-00774540].
301. Kano K, Nishikura K, Yamada Y, Arisaka O. No effect of fluvastatin on the bone mineral density of children with minimal change glomerulonephritis and some focal mesangial cell proliferation, other than an ameliorating effect on their proteinuria. Clinical Nephrology 2005;63(2):74-9. [MEDLINE: 15730048].
302. Kostapanos MS, Milionis HJ, Saougos VG, Lagos KG, Kostara C, Bairaktari ET, et al.Dose-dependent effect of rosuvastatin treatment on urinary protein excretion. Journal of Cardiovascular Pharmacology & Therapeutics 2007;12(4):292-7. [MEDLINE: 18172223].
303. Mackie FE, Rosenberg AR, Harmer JA, Kainer G, Celermajer DS. HMG CoA reductase inhibition and endothelial function in children with chronic kidney disease (CKD)--a pilot study. Acta Paediatrica 2010;99(3):457-9. [MEDLINE: 20050832].
304. Van Zuilen AD, Wetzels JF, Bots ML, Van Blankestijn PJ, MASTERPLAN Study Group. MASTERPLAN: study of the role of nurse practitioners in a multifactorial intervention to reduce cardiovascular risk in chronic kidney disease patients. Journal of Nephrology 2008;21(3):261-7. [MEDLINE: 18587712].
305. van Zuilen A, Blankestijn P, Bots M, Wetzels J, MASTERPLAN SG. Achievement of treatment-goals in patients with chronic kidney disease [abstract no: SP321]. Nephrology Dialysis Transplantation 2006;21(Suppl 4):iv120. [CENTRAL: CN-00602090].
306. van Zuilen AD, Blankestijn PJ, Bots M, Wetzels JF, The Masterplan Study Group. Determinants of blood pressure control in patients with chronic kidney disease (CKD) [abstract no: SA-PO904]. Journal of the American Society of Nephrology 2007;18(Abstracts):541A-2A. [CENTRAL: CN-00774317].
307. van Zuilen AD, Blankestijn PJ, Bots ML, Wetzels JF, MASTERPLAN Study Group. Achievement of treatment-goals in patients with chronic kidney disease (CKD) [abstract no: F-PO032]. Journal of the American Society of Nephrology 2006;17(Abstracts):343A. [CENTRAL: CN-00602092].
308. van Zuilen AD, Blankestijn PJ, Wetzels JF. Treatment center is an independent predictor of quality of control of cardiovascular risk factors in patients with CKD: baseline results of MASTERPLAN [abstract no: TH-PO907]. Journal of the American Society of Nephrology 2008;19(Abstracts Issue):315A. [CENTRAL: CN-00776790].
309. van Zuilen AD, Blankestijn PJ, van Buren M, ten Dam MA, Kaasjager KA, Ligtenberg G, et al.Quality of care in patients with chronic kidney disease is determined by hospital specific factors. Nephrology Dialysis Transplantation 2010;25(11):3647-54. [MEDLINE: 20382963].
310. van Zuilen AD, Nguyen K, Blankestijn PJ, Bots ML, Wetzels JF, MASTERPLAN Study Group. High prevalence of unrecognized myocardial infarction in patients with chronic kidney disease (CKD) [abstract no: F-PO033]. Journal of the American Society of Nephrology 2006;17(Abstracts):344A. [CENTRAL: CN-00602091].
311. van Zuilen AD, Wetzels JF, Blankestijn PJ, Bots ML, Van Buren M, ten Dam MA, et al.Rationale and design of the MASTERPLAN study: Multifactorial approach and superior treatment efficacy in renal patients with the aid of nurse practitioners. Journal of Nephrology 2005;18(1):30-4. [MEDLINE: 15772920].
312. van Zuilen AD, Wetzels JF, Blankestijn PJ, Bots ML, van Buren M, ten Dam MA, et al.Design and baseline characteristics of the Masterplan study (multifactorial approach and superior treatment efficacy in renal patients with the aid of nurse practitioners [abstract no: SP164]. Nephrology Dialysis Transplantation 2005;20(Suppl 5):v74. [CENTRAL: CN-00653707].
313. van Zuilen AD, van der Tweel I, Blankestijn PJ, Bots ML, van Buren M, ten Dam MA, et al.Multifactorial approach and superior treatment efficacy in renal patients with the aid of nurse practitioners. Design of The MASTERPLAN Study [ISRCTN73187232]. Trials [Electronic Resource] 2006;7:8. [MEDLINE: 16573836].
314. Nakamura T, Ushiyama C, Hirokawa K, Osada S, Shimada N, Koide H. Effect of cerivastatin on urinary albumin excretion and plasma endothelin-1 concentrations in type 2 diabetes patients with microalbuminuria and dyslipidemia. American Journal of Nephrology 2001;21(6):449-54. [MEDLINE: 11799261].
315. Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Ueda Y, Suzuki T, et al.Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner. Pharmacological Research 2010;61(1):58-61. [MEDLINE: 19666118].
316. Ott C, Schlaich MP, Schmidt BM, Titze SI, Schaufele T, Schmieder RE. Rosuvastatin improves basal nitric oxide activity of the renal vasculature in patients with hypercholesterolemia. Atherosclerosis 2008;196(2):704-11. [MEDLINE: 17298834].
317. Paniagua JA, Lopez-Miranda J, Escribano A, Berral FJ, Marin C, Bravo D, et al.Cerivastatin improves insulin sensitivity and insulin secretion in early-state obese type 2 diabetes. Diabetes 2002;51(8):2596-603. [MEDLINE: 12145176].
318. Paniagua JA, Lopez-Miranda J, Perez-Martinez P, Marin C, Vida JM, Fuentes F, et al.Oxidized-LDL levels are changed during short-term serum glucose variations and lowered with statin treatment in early Type 2 diabetes: a study of endothelial function and microalbuminuria. Diabetic Medicine 2005;22(12):1647-56. [MEDLINE: 16401307].
319. Paulsen L, Matthesen SK, Bech JN, Starklint J, Pedersen EB. Acute effects of atorvastatin on glomerular filtration rate, tubular function, blood pressure, and vasoactive hormones in patients with type 2 diabetes. Journal of Clinical Pharmacology 2010;50(7):816-22. [MEDLINE: 20056802].
320. Rammos G, Tseke P, Markaki P, Pantelias K, Kolovou K, Koloniaris A, et al.The role of statins in diabetic microalbuminuria [abstract no: MP123]. Nephrology Dialysis Transplantation 2005;20(Suppl 5):v241. [CENTRAL: CN-00776694].
321. Samuelsson O, Attman PO, Knight-Gibson C, Kron B, Larsson R, Mulec H, et al.Effect of gemfibrozil on lipoprotein abnormalities in chronic renal insufficiency: a controlled study in human chronic renal disease. Nephron 1997;75(3):286-94. [MEDLINE: 9069450].
322. Schmieder RE, Schneider MP, Delles C, Oehmer S, John S. Evidence for the lipid independent effects of statins on endothelial function [abstract]. Nephrology Dialysis Transplantation 2003;18(Suppl 4):359. [CENTRAL: CN-00447626].
323. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. New England Journal of Medicine 2008;358(6):580-91. [MEDLINE: 18256393].
324. Gaede P, Parving H, Pedersen O. Multifactorial intervention in patients with type 2 diabetes: long-term effects on mortality and vascular complications [abstract no: SA-FC042]. Journal of the American Society of Nephrology 2007;18(Abstracts):43A. [CENTRAL: CN-00740461].
325. Gaede P, Valentine WJ, Palmer AJ, Tucker DM, Lammert M, Parving HH, et al.Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study. Diabetes Care 2008;31(8):1510-5. [MEDLINE: 18443195].
326. Gaede P, Vedel P, Larsen N, Jensen G, Parving HH, Pedersen O. The STENO-2 study: intensified multifactorial intervention reduces the risk of cardiovascular disease in patients with type 2 diabetes and microalbuminuria [abstract no: F-FC031]. Journal of the American Society of Nephrology 2002;13(September, Program & Abstracts):72A. [CENTRAL: CN-00445410].
327. Gaede P, Vedel P, Larsen N, Jensen G, Parving HH, Pedersen O. The Steno-2 study: intensified multifactorial intervention reduces the risk of cardiovascular disease in patients with Type 2 diabetes and microalbuminuria [abstract no: 181]. 38th Annual Meeting of the European Association for the Study of Diabetes (EASD); 2002 Sept 1-5; Budapest, Hungary. 2002.
328. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. New England Journal of Medicine 2003;348(5):383-93. [MEDLINE: 12556541].
329. Gaede P, Vedel P, Obel J, Parving HH, Pedersen O. Intensive multifactorial intervention in NIDDM patients with persistent microalbuminuria [abstract]. Journal of the American Society of Nephrology 1996;7(9):1357. [CENTRAL: CN-00445411].
330. Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999;353(9153):617-22. [MEDLINE: 10030326].
331. Gaede PH, Jepsen PV, Parving HH, Pedersen OB. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno-2 study [Intensiveret multifaktoriel intervention hos patienter med type 2-diabetes mellitus og mikroalbuminuri: Steno-2-studiet]. Ugeskrift for Laeger 1999;161(30):4277-85. [MEDLINE: 10439688].
332. Tokunaga M, Tamura M, Anai H, Kabashima N, Serino R, Matsuo H, et al.Short-term efficacy and safety of telmisartan in patients with advanced chronic renal failure. [abstract no: PUB304]. Journal of the American Society of Nephrology 2004;15(Oct):827A. [CENTRAL: CN-00583284].
333. Tonolo G, Velussi M, Brocco E, Abaterusso C, Carraro A, Morgia G, et al.Simvastatin maintains steady patterns of GFR and improves AER and expression of slit diaphragm proteins in type II diabetes. Kidney International 2006;70(1):177-86. [MEDLINE: 16710349].
334. Torraca S, Nazzaro P, Visciano B, Pisani A, Di Micco L, Caputo DL, et al.Effects of high doses of atorvastatin (ATO) on renal dynamics and vascular reactivity in patients with chronic renal failure (CRF) [abstract no: MP272]. Nephrology Dialysis Transplantation 2006;21(Suppl 4):iv390. [CENTRAL: CN-00774679].
335. Landray M, Baigent C, Leaper C, Adu D, Altmann P, Armitage J, et al.The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD. American Journal of Kidney Diseases 2006;47(3):385-95. [MEDLINE: 16490616].
336. Landray M, Baigent C, Leaper C, the UK-HARP Steering Committee. Biochemical safety and efficacy of co-administration of ezetimibe and simvastatin among patients with chronic kidney disease: the second UK-heart and renal protection (UK-HARP-II) study [abstract]. Nephrology Dialysis Transplantation 2003;18(Suppl 4):119-20. [CENTRAL: CN-00446268].
337. van Dijk MA, Kamper AM, van Veen S, Souverijn JH, Blauw GJ. Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease. Nephrology Dialysis Transplantation 2001;16(11):2152-7. [MEDLINE: 11682660].
338. Yasuda G, Ando D, Hirawa N, Umemura S. Effects of atorvastatin versus probucol on low-density lipoprotein subtype distribution and renal function in hyperlipidemic patients with nondiabetic nephropathy. Renal Failure 2010;32(6):680-6. [MEDLINE: 20540635].
339. Yigit F, Muderrisoglu H, Guz G, Bozbas H, Korkmaz ME, Ozin MB, et al.Comparison of intermittent with continuous simvastatin treatment in hypercholesterolemic patients with end stage renal failure. Japanese Heart Journal 2004;45(6):959-68. [MEDLINE: 15655271].
340. Tamura K. Effects of statin on renal function in patients with chronic kidney disease. apps.who.int/trialsearch/Trial.aspx?TrialID=JPRN-UMIN000002526 (accessed 2 May 2014).
341. NCT00680017. A 30 week study of the combination of ABT-335 and rosuvastatin compared to rosuvastatin monotherapy for subjects with dyslipidemia and stage 3 chronic kidney disease. http://clinicaltrials.gov/show/NCT00680017 (accessed 2 May 2014).
342. Agharazii M. The renal protective effects of low-dose and high-dose atorvastatin in patients with glomerular disease and proteinuria: a randomized controlled double blinded study. http://clinicaltrials gov/ct2/show/NCT00768638 (accessed 2 May 2014).
343. Christensen F. The effects of atorvastatin on the NO-system in patients with type 2 diabetes and nephropathy. http://clinicaltrials.gov/ct2/show/NCT01208701 (accessed 2 May 2014).
344. Christensen F. The effects of atorvastatin on the nitric oxide-system in patients med non-diabetic nephropathy. www.clinicaltrials.gov/ct2/show/NCT01213498 (accessed 2 May 2014).
345. NCT00296400. Randomised, double-blind, 52-wk, parallel-grp multicentre, PIIb study to evaluate effects of rosuvastatin 10mg, rosuvastatin 40mg and atorvastatin 80mg on urinary protein excretion in hypercholesterolaemic non-diabetic patients with moderate proteinuria. www.clinicaltrials.gov/ct2/show/NCT00296400 (accessed 2 May 2014).
346. NCT00296374. Randomised, double-blind, 52-wk, parallel-grp, multicentre, PIIb study to evaluate effects of rosuvastatin 10mg, rosuvastatin 40mg and atorvastatin 80mg on urinary protein excretion in hypercholesterolaemic diabetic patients with moderate proteinuria. www.clinicaltrials.gov/ct2/show/NCT00296374 (accessed 2 May 2014).
347. Satta A. The metabolic and anti-Inflammatory effects of combined ezetimibe and simvastatin therapy, as compared to simvastatin alone, in patients with chronic proteinuric nephropathy. www.clinicaltrials.gov/ct2/show/NCT00861731 (accessed 28 April 2014).
348. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, et al.Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. New England Journal of Medicine 2004;351(13):1285-95. [MEDLINE: 15385655].
349. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al.Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet 2005;366(9493):1267-78. [MEDLINE: 16214597].
350. Boutron I, Dutton S, Ravaud P, Altman DG. Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes. JAMA 2010;303(20):2058-64. [MEDLINE: 20501928].
351. Briel M, Schwartz GG, Thompson PL, de Lemos JA, Blazing MA, van Es GA, et al.Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials. JAMA 2006;295(17):2046-56. [MEDLINE: 16670413].
352. Campese VM, Nadim MK, Epstein M. Are 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors renoprotective?. Journal of the American Society of Nephrology 2005;16 Suppl 1:S11-7. [MEDLINE: 15938026].
353. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al.Prevalence of chronic kidney disease in the United States. JAMA 2007;298(17):2038-47. [MEDLINE: 17986697].
354. Couser WG, Remuzzi G, Mendis S, Tonelli M. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney International 2011;80(12):1258-70. [MEDLINE: 21993585].
355. Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al.Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170, 000 participants in 26 randomised trials. Lancet 2010;376(9753):1670-81. [MEDLINE: 21067804].
356. Di Angelantonio E, Chowdhury R, Sarwar N, Aspelund T, Danesh J, Gudnason V. Chronic kidney disease and risk of major cardiovascular disease and non-vascular mortality: prospective population based cohort study. BMJ 2010;341:c4986. [MEDLINE: 20884698].
357. Drueke TB, Nguyen Khoa T, Massy ZA, Witko-Sarsat V, Lacour B, Descamps-Latscha B. Role of oxidized low-density lipoprotein in the atherosclerosis of uremia. Kidney International - Supplement 2001;78:S114-9. [MEDLINE: 11168995].
358. Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000;56(2):455-63. [MEDLINE: 10877304].
359. Smith JP. Clinical Briefing Document. Endocrinologic and Metabolic Drugs Advisory Committee Meeting. November 2, 2011. New Drug Application 21-687/S-039: Vytorin® (ezetimibe/simvastatin). New Drug Application 21-445/S-033:Zetia® (ezetimibe). Food and Drug Administration, 2011. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm277649.pdf (accessed 2 May 2014).
360. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. American Journal of Kidney Diseases 1998;32(5 Suppl 3):S112-9. [MEDLINE: 9820470].
361. Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, et al.Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. Journal of the American Society of Nephrology 2005;16(2):489-95. [MEDLINE: 15590763].
362. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. New England Journal of Medicine 2004;351(13):1296-305. [MEDLINE: 15385656].
363. Grassmann A, Gioberge S, Moeller S, Brown G. ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends. Nephrology Dialysis Transplantation 2005;20(12):2587-93. [MEDLINE: 16204281].
364. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al.GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-6. [MEDLINE: 18436948].
365. Harbord RM, Egger M, Sterne JA. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Statistics in Medicine 2006;25(20):3443-57. [MEDLINE: 16345038].
366. Harris K, Thomas M, Short C, Moore R. Assessment of the efficacy of treatment of dyslipidemia in renal outpatients. Journal of Nephrology 2002;15(3):263-9. [MEDLINE: 12113597].
367. Henry RM, Kostense PJ, Bos G, Dekker JM, Nijpels G, Heine RJ, et al.Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study. Kidney International 2002;62(4):1402-7. [MEDLINE: 12234312].
368. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60. [MEDLINE: 12958120].
369. Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org. The Cochrane Collaboration. 2011.
370. Kasiske BL, O'Donnell MP, Garvis WJ, Keane WF. Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure. Circulation Research 1988;62(3):367-74. [MEDLINE: 3338121].
371. KDIGO. Clinical practice guidelines. http://kdigo.org/home/guidelines/ (accessed 2 May 2014).
372. K/DOQI. Clinical practice guidelines for managing dyslipidemias in chronic kidney disease: III. Treating dyslipidemias. American Journal of Kidney Diseases 2003;41(4 Suppl 3):S39-S58. [EMBASE: 2003140838].
373. Keane WF. The role of lipids in renal disease: future challenges. Kidney International - Supplement 2000;75:S27-31. [MEDLINE: 10828758].
374. Kinlay S, Selwyn AP. Effects of statins on inflammation in patients with acute and chronic coronary syndromes. American Journal of Cardiology 2003;91(4A):9B-13B. [MEDLINE: 12615293].
375. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al.National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Annals of Internal Medicine 2003;139(2):137-47. [MEDLINE: 12859163].
376. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New England Journal of Medicine 1998;339(19):1349-57. [MEDLINE: 9841303].
377. Manjunath G, Tighiouart H, Ibrahim H, MacLeod B, Salem DN, Griffith JL, et al.Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. Journal of American College of Cardiology 2003;41(1):47-55. [MEDLINE: 12570944].
378. Massy ZA, Guijarro C. Statins: effects beyond cholesterol lowering. Nephrology Dialysis Transplantation 2001;16(9):1738-41. [MEDLINE: 11522848].
379. Muntner P, He J, Astor BC, Folsom AR, Coresh J. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. Journal of the American Society of Nephrology 2005;16(2):529-38. [MEDLINE: 15625072].
380. National Institute for Health and Clinical Excellence. Statins for the prevention of cardiovascular events. Understanding NICE guidance - information for people who have or are at increased risk of cardiovascular disease, their families and the public. National Institute for Health and Clinical Excellence. NHS (UK), 2006. http://www.nice.org.uk/nicemedia/live/11564/33155/33155.pdf (accessed 2 May 2014).
381. Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Perkovic V, Nigwekar SU, et al.HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database of Systematic Reviews 2013, Issue 9. [DOI: 10.1002/14651858.CD004289.pub5].
382. Palmer SC, Navaneethan SD, Craig JC, Perkovic V, Johnson DW, Nigwekar SU, et al.HMG CoA reductase inhibitors (statins) for kidney transplant recipients. Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD005019.pub4].
383. Robinson JG, Smith B, Maheshwari N, Schrott H. Pleiotropic effects of statins: benefit beyond cholesterol reduction. A meta-regression analysis. Journal of the American College of Cardiology 2005;46(10):1855-62. [MEDLINE: 16286171].
384. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al.The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New England Journal of Medicine 1996;335(14):1001-9. [MEDLINE: 8801446].
385. Schaeffner ES, Kurth T, Curhan GC, Glynn RJ, Rexrode KM, Baigent C, et al.Cholesterol and the risk of renal dysfunction in apparently healthy men. Journal of the American Society of Nephrology 2003;14(8):2084-91. [MEDLINE: 12874462].
386. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al.Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. New England Journal of Medicine 1995;333(20):1301-7. [MEDLINE: 7566020].
387. Shlipak MG, Fried LF, Cushman M, Manolio TA, Peterson D, Stehman-Breen C, et al.Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA 2005;293(14):1737-45. [MEDLINE: 15827312].
388. Sotiriou CG, Cheng JW. Beneficial effects of statins in coronary artery disease--beyond lowering cholesterol. Annals of Pharmacotherapy 2000;34(12):1432-9. [MEDLINE: 11144702].
389. USRDS. United States Renal Data System. Chapter 4. Cardiovascular disease in patients with end-stage renal disease. http://www.usrds.org/2011/pdf/v2_ch04_11.pdf (accessed 2 May 2014).
390. Walker R. Lipid lowering therapy in patients with chronic kidney disease. http://www.cari.org.au/Archived%20guidelines/CKD%20archived/Lipid_Lowering_Therapy.pdf (accessed May 2014).
391. Weiner DE, Tabatabai S, Tighiouart H, Elsayed E, Bansal N, Griffith J, et al.Cardiovascular outcomes and all-cause mortality: exploring the interaction between CKD and cardiovascular disease. American Journal of Kidney Diseases 2006;48(3):392-401. [MEDLINE: 16931212].
392. Navaneethan SD, Pansini F, Perkovic V, Manno C, Pellegrini F, Johnson DW, et al.HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: 10.1002/14651858.CD007784].
393. Strippoli GF, Navaneethan SD, Johnson D, Perkovic V, Pellegrini F, Nicolucci A, et al.Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ 2008;336(7645):645-51. [MEDLINE: 18299289].